Intracranial Hemorrhages
Conditions
Keywords
Intracranial Hemorrhage, Colchicine
Brief summary
The overall goal is to establish the safety and efficacy of colchicine in ICH patients for the prevention of major cardiovascular events and brain injury. Colchicine for the prevention of vascular events after an acute intracerebral hemorrhage (CoVasc-ICH) is a vanguard pilot trial designed to obtain the factual feasibility prerequisites essential for the planning, design, funding and execution of a subsequent phase III trial.
Interventions
DRUGColchicine Pill
Anti-inflammatory
OTHERPlacebo
Inert ingredients
Sponsors
Population Health Research Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
Investigational product, with matching placebo
Intervention model description
Feasibility, double-blind, placebo-controlled randomized controlled trial (RCT)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Adult participants are eligible to be included in the study only if all of the following criteria apply: Type of Participant and Disease Characteristics 1. Participants with documented spontaneous intraparenchymal hemorrhage within 48 hours of symptom onset (or last seen normal) and 2. Qualifying for at least one of the following categories: i. history of symptomatic coronary, peripheral and/or carotid artery disease (severe atherosclerotic vascular disease), or ii. visualized extracranial cervical/intracranial atherosclerotic disease causing any degree of stenosis/occlusion or presence of aortic arch plaque with maximum thickness ≥1 mm (moderate atherosclerotic vascular disease), or iii. two or more risk factors including: age 60 years or older, hypertension, dyslipidemia, diabetes mellitus, chronic kidney disease (eGFR: 15-50mL/min), history of ischemic stroke or current smoking (mild atherosclerotic vascular disease) Informed Consent 3. Capable of giving signed informed consent either independently, or by a legally authorized representative (LAR), which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Exclusion criteria
Participants are excluded from the study if any of the following criteria apply: Medical Conditions 1. Secondary causes of ICH (relating to trauma, macrovascular anomalies, neoplasms or bleeding diathesis) 2. Inflammatory bowel disease or chronic diarrhea 3. Cirrhosis or severe hepatic dysfunction 4. Renal insufficiency (eGFR \<15mL/min) Prior/Concomitant Therapy 5. Concurrent treatment with strong CYP3A4 inhibitors (atazanavir, clarithromycin, darunavir/ritonavir, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, tipranavir/ritonavir) or P-gp inhibitors (cyclosporine, ranolazine) 6. Known allergy or sensitivity to colchicine 7. Strong indication for colchicine where assignment to placebo is deemed unacceptable Other Exclusions 8. Pregnant or breast-feeding 9. Inability to adhere to study procedures 10. Estimated life expectancy less than 6 months at the time of enrollment 11. Close affiliation with the investigational site; e.g. a close relative of the investigator, dependent person (e.g., employee or student of the investigational site)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility - Recruitment | From site activation until the end of recruitment (approximately 18 months) | Recruitment Rate, mean of approximately 10 participants per site, per year |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Feasibility - Refusal Rate | Exploratory, from first patient, first visit, until the common study end date (approximately 30 months) | Refusal to participate is not a substantial barrier to recruitment |
| Feasibility - Retention Rate | At 6 months from randomization | Retention of ≥90% of study participants |
| Feasibility - Medication Adherence | At 12 months from randomization | Adherence \>75% |
Countries
Canada
Outcome results
None listed